These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 28970215)

  • 21. Effect of disease modifying agents on the lipid profiles of patients with rheumatoid arthritis.
    Munro R; Morrison E; McDonald AG; Hunter JA; Madhok R; Capell HA
    Ann Rheum Dis; 1997 Jun; 56(6):374-7. PubMed ID: 9227167
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardiovascular risk in rheumatoid arthritis versus osteoarthritis: acute phase response related decreased insulin sensitivity and high-density lipoprotein cholesterol as well as clustering of metabolic syndrome features in rheumatoid arthritis.
    Dessein PH; Stanwix AE; Joffe BI
    Arthritis Res; 2002; 4(5):R5. PubMed ID: 12223108
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.
    Stevenson M; Archer R; Tosh J; Simpson E; Everson-Hock E; Stevens J; Hernandez-Alava M; Paisley S; Dickinson K; Scott D; Young A; Wailoo A
    Health Technol Assess; 2016 Apr; 20(35):1-610. PubMed ID: 27140438
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Longterm Hydroxychloroquine Therapy and Low-dose Aspirin May Have an Additive Effectiveness in the Primary Prevention of Cardiovascular Events in Patients with Systemic Lupus Erythematosus.
    Fasano S; Pierro L; Pantano I; Iudici M; Valentini G
    J Rheumatol; 2017 Jul; 44(7):1032-1038. PubMed ID: 28507183
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Effect of TNFα-Inhibitors on Cardiovascular Events in Patients with Rheumatoid Arthritis: An Updated Systematic Review of the Literature.
    Sattin M; Towheed T
    Curr Rheumatol Rev; 2016; 12(3):208-222. PubMed ID: 27041084
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased lipid levels but unchanged atherogenic index in rheumatoid arthritis patients treated with biologic disease modifying antirheumatic drugs: published experience.
    Schimmel EK; Yazici Y
    Clin Exp Rheumatol; 2009; 27(3):446-51. PubMed ID: 19604437
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Incident diabetes associated with hydroxychloroquine, methotrexate, biologics and glucocorticoids in rheumatoid arthritis: A systematic review and meta-analysis.
    Xie W; Yang X; Ji L; Zhang Z
    Semin Arthritis Rheum; 2020 Aug; 50(4):598-607. PubMed ID: 32480098
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Methotrexate, hydroxychloroquine, and intramuscular gold in rheumatoid arthritis: relative area under the curve effectiveness and sequence effects.
    Hurst S; Kallan MJ; Wolfe FJ; Fries JF; Albert DA
    J Rheumatol; 2002 Aug; 29(8):1639-45. PubMed ID: 12180722
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk of diabetes mellitus associated with disease-modifying antirheumatic drugs and statins in rheumatoid arthritis.
    Ozen G; Pedro S; Holmqvist ME; Avery M; Wolfe F; Michaud K
    Ann Rheum Dis; 2017 May; 76(5):848-854. PubMed ID: 27836820
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis.
    Solomon DH; Massarotti E; Garg R; Liu J; Canning C; Schneeweiss S
    JAMA; 2011 Jun; 305(24):2525-31. PubMed ID: 21693740
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Rheumatoid arthritis--possible risk marker of cardiovascular disease].
    Jonsson SW; Dahlqvist SR
    Lakartidningen; 2004 Nov; 101(46):3672, 3674-5. PubMed ID: 15586491
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis.
    Munster T; Gibbs JP; Shen D; Baethge BA; Botstein GR; Caldwell J; Dietz F; Ettlinger R; Golden HE; Lindsley H; McLaughlin GE; Moreland LW; Roberts WN; Rooney TW; Rothschild B; Sack M; Sebba AI; Weisman M; Welch KE; Yocum D; Furst DE
    Arthritis Rheum; 2002 Jun; 46(6):1460-9. PubMed ID: 12115175
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hydroxychloroquine and the risk of respiratory infections among RA patients.
    Kremer JM; Reed G; Pappas DA; Harold LR; Kane K; Greenberg J; Winthrop K
    RMD Open; 2020 Nov; 6(3):. PubMed ID: 33161375
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hydroxychloroquine and risk of osteoporosis in patients with rheumatoid arthritis: A population-based retrospective study of 6408 patients.
    Dong C; Chen BS; Wu CH; Chiu YM; Liao PL; Perng WT
    Int J Rheum Dis; 2024 Aug; 27(8):e15286. PubMed ID: 39154356
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis.
    Gabay C; McInnes IB; Kavanaugh A; Tuckwell K; Klearman M; Pulley J; Sattar N
    Ann Rheum Dis; 2016 Oct; 75(10):1806-12. PubMed ID: 26613768
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of antirheumatic therapy on serum lipid levels in patients with rheumatoid arthritis: a prospective study.
    Park YB; Choi HK; Kim MY; Lee WK; Song J; Kim DK; Lee SK
    Am J Med; 2002 Aug; 113(3):188-93. PubMed ID: 12208376
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Awareness and perceived risk of cardiovascular disease among individuals living with rheumatoid arthritis is low: results of a systematic literature review.
    Ghosh-Swaby OR; Kuriya B
    Arthritis Res Ther; 2019 Jan; 21(1):33. PubMed ID: 30670075
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk of depression, suicide and psychosis with hydroxychloroquine treatment for rheumatoid arthritis: a multinational network cohort study.
    Lane JCE; Weaver J; Kostka K; Duarte-Salles T; Abrahao MTF; Alghoul H; Alser O; Alshammari TM; Areia C; Biedermann P; Banda JM; Burn E; Casajust P; Fister K; Hardin J; Hester L; Hripcsak G; Kaas-Hansen BS; Khosla S; Kolovos S; Lynch KE; Makadia R; Mehta PP; Morales DR; Morgan-Stewart H; Mosseveld M; Newby D; Nyberg F; Ostropolets A; Woong Park R; Prats-Uribe A; Rao GA; Reich C; Rijnbeek P; Sena AG; Shoaibi A; Spotnitz M; Subbian V; Suchard MA; Vizcaya D; Wen H; Wilde M; Xie J; You SC; Zhang L; Lovestone S; Ryan P; Prieto-Alhambra D;
    Rheumatology (Oxford); 2021 Jul; 60(7):3222-3234. PubMed ID: 33367863
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cardiovascular Disease Risk in Older Adults and Elderly Patients with Rheumatoid Arthritis: What Role Can Disease-Modifying Antirheumatic Drugs Play in Cardiovascular Risk Reduction?
    Day AL; Singh JA
    Drugs Aging; 2019 Jun; 36(6):493-510. PubMed ID: 30953327
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: a systematic literature review.
    Roubille C; Haraoui B
    Semin Arthritis Rheum; 2014 Apr; 43(5):613-26. PubMed ID: 24231065
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.